TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03202953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ventilation strategy 1
Description: In Group I, after trendelenburg position, patients will be applied 1:1 ratio VCV.~* Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ventilation strategy 2
Description: In group A, after trendelenburg position, patients will be applied autoflow VCV.~- Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
Study: NCT01404364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 0,3mL intravitreal injection of Triamcinolone, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpromazine
Description: 2,5mL Chlorpromazine retrobulbar injection, single dose
Study: NCT02341742

Intervention type: DEVICE
Intervention: multiple examinations
Description: biological,clinical, X-ray, DXA, accelerometry assessment
Study: NCT02369068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A
Description: Intravaginal pelvic floor injection one series

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog
Description: Intravaginal pelvic floor injection one series
Study: NCT01745692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous rtPA
Description: All patients receive IV alteplase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous rtPA
Description: All patients receive IV alteplase
Study: NCT00468143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall ® Immediate Release
Description: Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall ® Immediate Release
Description: Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall XR ®
Description: Adderall Extended Release (XR) was provided as treatment for three weeks at (15, 30, or 45 mg QD). The medication was optimized for titration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall XR ®
Description: Adderall Extended Release (XR) was provided as treatment for three weeks at (15, 30, or 45 mg QD). The medication was optimized for titration.
Study: NCT00218049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBR 12909
Description: 50mg GBR 12909 over 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBR 12909
Description: GBR 12909 75 mg over 12 day period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBR 12909
Description: GBR 12909 100 mg over 12 day period
Study: NCT02334475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: single intraarticular injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: single injection 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml)
Study: NCT02755870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CNM-Au8
Description: Clene's technology integrates nanotechnology, materials science, plasma conditioning (corona discharge), and hydro-electrocrystallization to create a new nanocatalytic drug class

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
Study: NCT04160026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine
Description: Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly intermittent preventive treatment with sulfadoxine-pyrimethamine
Description: Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine with targeted information transfer
Description: Feasibility study to assess adherence to guidelines among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
Study: NCT00932542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eutectic mixture
Description: The eutectic mixture of lidocaine + prilocaine + bupivacaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2,5%; prilocaine 2,5%
Description: lidocaine 2,5%; prilocaine 2,5%
Study: NCT01962532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: JNJ-42756493
Description: JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: JNJ-42756493
Description: JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: JNJ-42756493
Description: Recommended Phase 2 JNJ-42756493 dose determined in Part 1 administered orally for 28-days cycles (Intermitting dosing regimen).
Study: NCT00900224

Intervention type: GENETIC
Intervention: DNA analysis

Intervention type: GENETIC
Intervention: DNA methylation analysis

Intervention type: GENETIC
Intervention: gene expression analysis

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: GENETIC
Intervention: polymerase chain reaction

Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: OTHER
Intervention: high performance liquid chromatography

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT01005082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low salt diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water therapy alone
Study: NCT02803008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - SR15-46-Z13-072)
Study: NCT00522821

Intervention type: DRUG
Group type: OTHER
Intervention: intravenous immunoglobulins
Description: * Adults: 600 mg/kg bodyweight every 3 weeks~* Children: 800 mg/kg bodyweight every 3 week

Intervention type: DRUG
Group type: OTHER
Intervention: intravenous immunoglobulins
Description: * Adults: 600 mg/kg bodyweight every 3 weeks~* Children: 800 mg/kg bodyweight every 3 week

Intervention type: DRUG
Group type: OTHER
Intervention: antibiotics
Description: * Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~* Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid.

Intervention type: DRUG
Group type: OTHER
Intervention: antibiotics
Description: * Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~* Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid.
Study: NCT03114293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: The app includes an EBPI and physical activity feedback
Study: NCT03843372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula
Description: All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: All of participants will be received one night high flow nasal cannula and another night for continuous positive airway pressure.
Study: NCT00572260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin 6 mg/kg IV
Description: daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)
Study: NCT04010409

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04163848

Intervention type: OTHER
Intervention: Pollution
Description: CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery

Intervention type: OTHER
Intervention: Pollution
Description: CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
Study: NCT02310074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulsatile Gonadotropin Releasing Hormone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: Human chorionic gonadotropin (hCG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urinary Follicle-Stimulating Hormone
Description: Urinary Follicle-Stimulating Hormone (uFSH)
Study: NCT03769649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CelluTite
Description: CelluTite: Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
Study: NCT03240419

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Bifidobacterium BB12 and Lactobacillus Rhamosus LGG (50%:50%) capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule manufactured to mimic probiotic capsules.
Study: NCT03163641

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys
Description: Bandage Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ocular Bandage Gel
Description: 0.75% crosslinked HA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ocular Bandage Gel
Description: 0.75% crosslinked HA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ocular Bandage Gel
Description: 0.75% crosslinked HA
Study: NCT04789031

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS)
Description: Patients received a renal specific ONS (Novasource Renal, Nestle) providing 475 kcal and 21.7g of protein per serving on a daily basis for 6 months. This was a ready-to- drink formula available in a tetrabrik pack. Patients consumed the product 30 minutes after commencing their dialysis session or at home after completion of dialysis.
Study: NCT01661764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentanoic acid and docosahexanoic acid
Description: 1395 mg EPA plus 1125 mg DHA daily for 24 weeks
Study: NCT01421498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks
Study: NCT01661764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentanoic acid and docosahexanoic acid
Description: 1395 mg EPA plus 1125 mg DHA daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentanoic acid and docosahexanoic acid
Description: 1395 mg EPA plus 1125 mg DHA daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oleic Acid
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oleic Acid
Description: Placebo
Study: NCT01421498

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks
Study: NCT04067869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood sample containing 3 ethylene-diamine-tetra-acetic acid tubes (7ml), 3 dry tubes (7ml) and 5 citrated tubes, ie 9 tubes
Study: NCT00572091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTMA Implant
Description: Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
Study: NCT03165773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn grits
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
Study: NCT01765296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: 2 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 200 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule
Study: NCT01619852

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: .9 normal saline placebo
Description: Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group L (lidocaine)
Description: Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
Study: NCT01661764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oleic Acid
Description: Placebo
Study: NCT02536820

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychoneuroimmune therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Actual diabetes treatment in each participant
Study: NCT03586908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHP-201 0.5% ophthalmic solution (topical eye drop)
Description: D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2\~D6: PHP-201 0.5% topical eye drop OU TID
Study: NCT02826928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample withdrawn

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample withdrawn
Study: NCT01939444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone intranasal
Description: If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxone intravenous
Description: The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position
Study: NCT00805805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate
Description: 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime, for one week to test gastric tolerance. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. Serum ceruloplasmin levels measured weekly will be used as a surrogate measure of copper status, with a target of 10-15 mg/dl (normal 20-40). When target Cp levels are reached, usually in 4-8 weeks, a maintenance dose of usually 40-80 mg of TM/day, divided half with a major meal, and half away from food at bedtime will be established (vary from 10 mg to 120 mg/day).
Study: NCT00967577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: 70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
Study: NCT00805805

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 2 will basically mirror Arm 1 with the patients receiving 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime the first week. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. With the dosage being reduced at about the same frequency as the patients receiving TM
Study: NCT00002610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study: NCT04181372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib hydrochloride was given 12mg once daily for two weeks, stop for one week, each 3-week cycle for 2 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platinum-based chemotherapy medicine
Description: (1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m\^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m\^2 ,i.v. on day 1, pemetrexed was given 500 mg/m\^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m\^2 i.v. on day 1; docetaxel was given 75 mg/m\^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
Study: NCT00002610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT02758275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching: Individual (5606)
Description: Usual care and Teaching: Individual (5606): It consists of 6 educational sessions:~1. Behavior Modification (4360) Promotion of a behavior change.~2. Teaching Disease Process (5602) Assisting the patient to understand information related to a specific disease process.~3. Teaching: Prescribed Medication (5616) Preparing a patient to safely take prescribed medications and monitor for their effects.~4. Teaching: Prescribed Diet (5614) Preparing a patient to correctly follow a prescribed diet.~5. Teaching: Prescribed Exercise (5612) Preparing a patient to achieve and/or maintain a prescribed level of activity.~6. Coping Enhancement (5230) Assisting a patient to adapt to perceived stressors, changes, or threats that interfere with meeting life demands and roles.
Study: NCT01170676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Puff City GA
Description: Puff City GA focuses on three areas of health behavior: 1) adherence to controller medications; 2) immediate availability of rescue medication; 3)smoking cessation/reduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Asthma Education
Description: Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
Study: NCT00002610

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01709175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: This is a 13 week strength training program. Sessions will be supervised by a Certified Exercise Physiologist in a group setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: This is a 13 week strength training program. Sessions will be supervised by a Certified Exercise Physiologist in a group setting.
Study: NCT01184040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIP CM
Description: Participants will receive progressively increasing CM for walking 10,000 steps per day over 4 days prior to visit as verified by the pedometer.
Study: NCT02015208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progression or unacceptable toxicity develops.
Study: NCT00573859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADHD medication
Description: For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For the placebo condition, participants received placebo pills for two consecutive days.
Study: NCT02570919

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IGRT 45 Gy in 5 fractions of 9 Gy
Description: Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT 24 Gy single dose
Description: Administration of a single dose of 24 Gy in one session